February 22, 2024 11:41 AM ESTUpdated February 23, 04:46 AM
News Briefing

MD An­der­son buys tech from Bel­licum; Tar­sus’ Ly­me dis­ease tri­al da­ta; Rigel takes Gavre­to

Reynald Castañeda

Deputy Editor

Anna Brown

News Reporter

Kyle LaHucik

Senior Reporter

Plus, Oc­u­lar Ther­a­peu­tix’s pri­vate place­ment, Lim­maT­e­ch Bi­o­log­ics’ shigel­losis vac­cine da­ta and a col­lab­o­ra­tion be­tween Hox Ther­a­peu­tics and Ver­nalis.

MD An­der­son buys tech from Bel­licum …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times